Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Recurrent Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Unresectable Lung Non-Small Cell Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: ROR1 CAR-specific Autologous T-Lymphocytes
Sponsor: Fred Hutchinson Cancer Center
Collaborators: National Cancer Institute (NCI)